Funding Awards

Praetego

Mar 1, 2023

Praetego Awarded $0.3M by National Eye Institute to Advance Novel Oral Drug for Diabetic Retinopathy

Praetego Inc, a pharmaceutical company protecting patients from neurodegenerative diseases related to aging, is pleased to announce a $0.3M

Praetego

Oct 4, 2022

Praetego Awarded $2.5M by the NIH National Institute of Aging to Advance Novel Drug Candidate Against Alzheimer’s Disease

Praetego Inc, a pharmaceutical company committed to protecting patients from neurodegenerative diseases related to aging, is pleased to anno

Praetego

Sep 30, 2020

NIH Phase 2 STTR Funding Award

Praetego Inc. is pleased to announce the approval of a multi-year $2.1M STTR grant from the National Institute of Diabetes and Digestive and

Praetego

Jan 2, 2020

Phase 2 grant submitted to NIH/NIDDK

After a successful conclusion of the Phase 1 NIDDK grant, Praetego submits a Phase 2 SBIR/STTR grant.